XDx, Inc. Files Reexamination Request for Source MDx Patent
Published: Feb 15, 2008
BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company, announced today that it has filed an Inter Partes Reexamination requesting that the United States Patent and Trademark Office review certain claims of United States Patent No. 6,964,850 ("'850 Patent") assigned to Source MDx, Inc., entitled “Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles.” The '850 Patent purports to claim methods for creating an index of a subject’s biological state pertaining to inflammation. XDx’s request states that a combination of prior art references available before the '850 patent's earliest priority date raise substantial new questions about the patentability of certain of the patent’s claims.